Valuation dashboard for Dianthus Therapeutics, Inc. (DNTH) with P/E N/A, P/B 3.95, EV/EBITDA -152.3 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production,...
Analysis Summary
Trailing-twelve-month margins: gross margin 96.0%, operating margin -114.4%, net margin -15.7%.
At $82.70 (closing price, November 3, 2026), DNTH has negative trailing earnings (P/E not meaningful) and an ROE of -3.51%. Market capitalisation stands at $4.6B.
Balance sheet quality for DNTH: debt-to-equity ratio of 0.00, current ratio of 26.10 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.95 |
| EV / EBITDA | -152.3 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. | $4.6B | 3.95 | -3.5% | |
| IMVT | Immunovant, Inc. | $6.0B | 8.12 | -69.6% | |
| VERA | Vera Therapeutics, Inc. | $2.2B | 5.41 | -84.1% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $134.5B | 34.15 | 4.11 | 17.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $100.2B | 21.51 | 2.96 | 15.1% |
| MRNA | Moderna, Inc. | $91.2B | 13.38 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
Price
| Price | $82.70 (closing price, November 3, 2026) |
| Market Cap | $4.6B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -3.51% |
| Return on Invested Capital | -18.47% |
| Return on Assets | -2.47% |
| Gross Margin | 96.01% |
| Operating Margin | -11,441.39% |
| Net Margin | -1,570.85% |
Related companies: IMVT · VERA · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of DNTH: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks